13,148 Shares in Penumbra, Inc. $PEN Acquired by Candriam S.C.A.

Candriam S.C.A. purchased a new position in Penumbra, Inc. (NYSE:PEN) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,148 shares of the company’s stock, valued at approximately $3,374,000.

Several other institutional investors and hedge funds have also recently modified their holdings of PEN. Vanguard Group Inc. lifted its holdings in shares of Penumbra by 0.7% in the first quarter. Vanguard Group Inc. now owns 3,675,349 shares of the company’s stock worth $982,825,000 after buying an additional 24,727 shares in the last quarter. Geode Capital Management LLC increased its holdings in Penumbra by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 706,404 shares of the company’s stock valued at $181,314,000 after acquiring an additional 17,772 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Penumbra by 437.0% in the 1st quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company’s stock worth $188,159,000 after purchasing an additional 572,606 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Penumbra by 0.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 322,030 shares of the company’s stock valued at $80,726,000 after purchasing an additional 984 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Penumbra by 4.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 283,821 shares of the company’s stock valued at $75,897,000 after purchasing an additional 12,247 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Insider Activity

In related news, CEO Adam Elsesser sold 15,900 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $254.53, for a total transaction of $4,047,027.00. Following the transaction, the chief executive officer directly owned 170,280 shares in the company, valued at approximately $43,341,368.40. This represents a 8.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Thomas Wilder sold 186 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $253.93, for a total transaction of $47,230.98. Following the completion of the sale, the director directly owned 186 shares in the company, valued at $47,230.98. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 34,430 shares of company stock valued at $9,008,613 in the last quarter. 4.20% of the stock is currently owned by company insiders.

Penumbra Stock Performance

NYSE PEN opened at $280.33 on Friday. The business’s 50 day moving average price is $256.27 and its 200-day moving average price is $257.94. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $310.00. The company has a market cap of $10.98 billion, a P/E ratio of 74.56, a P/E/G ratio of 2.10 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.90 by $0.07. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The company had revenue of $354.69 million during the quarter, compared to analyst estimates of $340.77 million. During the same period in the previous year, the firm earned $0.85 earnings per share. Penumbra’s quarterly revenue was up 17.8% compared to the same quarter last year. Penumbra has set its FY 2025 guidance at EPS. Sell-side analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PEN. BTIG Research reaffirmed a “buy” rating and issued a $320.00 target price on shares of Penumbra in a report on Monday, October 27th. Royal Bank Of Canada reduced their price objective on Penumbra from $330.00 to $325.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $326.00 price objective on shares of Penumbra in a report on Monday, October 27th. JPMorgan Chase & Co. raised their target price on shares of Penumbra from $265.00 to $275.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Finally, Canaccord Genuity Group boosted their price target on shares of Penumbra from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $305.69.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.